BIO-STAT Injection

 Panacea to Halt Excessive Blood-Loss

COMPOSITION: Tranexamic Acid IP 500 mg/5 ml

  • Tranexamic acid is a synthetic derivative of the amino acid lysine that exerts its antifibrinolytic effect through the reversible blockade of lysine binding sites on plasminogen molecules. 
  • Intravenous administration caused reductions relative to placebo of 29-54% in postoperative blood losses in patients undergoing cardiac surgery with cardiopulmonary bypass.
  • Statistically significant reductions in postoperative blood losses and transfusion requirements in a number of types of surgery were reported.
  • Tranexamic acid was superior to dipyridamole in the reduction of postoperative blood losses.
  • Had similar efficacy to aprotinin and potential cost and tolerability advantages over aprotinin.
  • Also appears to reduce rates of mortality and urgent surgery in patients with upper gastrointestinal hemorrhage.
  • Reduces menstrual blood loss and is a possible alternative to surgery in menorrhagia, and has been used successfully to control bleeding in pregnancy.

CONTRAINDICATIONS: 

  • Active thromboembolic disease 
  • Severe renal failure
  • Hypersensitivity